Los Angeles, California, November 28, 2016 – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”) develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product, RP-G28, is being developed as potentially the first FDA-approved treatment for lactose intolerance. The Company announced today that it will be presenting at the 9th Annual LD Micro Main Event on Wednesday, December 7, 2016 at 11 am PST / 2 pm EST.
Ritter Pharmaceuticals’ management team will also be available to participate in one-on-one meetings with investors that week. Conference participants who are interested in scheduling a meeting are encouraged to sign up through the conference’s portal, or by calling Ellen Mochizuki at 310-203-1000.
The LD Micro Main Event is the largest independent conference for small / microcap companies and will feature 240 presenting companies. The conference will be held December 6-8, 2016 at the Luxe Sunset Boulevard Hotel, located at: 11461 Sunset Boulevard, Los Angeles, California.
The Company’s presentation will be available for the public to access at www.ritterpharma.com. View Ritter Pharmaceuticals’ profile here: http://www.ldmicro.com/profile/RTTR
About Ritter Pharmaceuticals, Inc.
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company is advancing human gut health research by exploring the metabolic capacity of gut microbiota, and translating the functionality of these microbiome modulators into safe and effective applications. Their lead drug candidate, RP-G28, has the potential to become the first FDA-approved drug for lactose intolerance, a condition that affects more than one billion people worldwide. The product is currently being evaluating in a Phase 2b/3 377-subject clinical trial.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).
This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to our release of topline results from our Phase 2b/3 clinical trial of RP-G28. Management believes that these forward-looking statements are reasonable as and when made. However, such statements involve a number of known and unknown risks and uncertainties that could cause the Company’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the drug development process generally, including the outcomes of planned clinical trials and the regulatory review process. For a discussion of certain risks and uncertainties affecting Ritter Pharmaceuticals’ forward-looking statements, please review the Company’s reports filed with the Securities and Exchange Commission, including, but not limited to, its Annual Report on Form 10-K for the period ended December 31, 2015 and Quarterly Reports on Form 10-Q for the periods ended March 31, 2016, June 30, 2016 and September 30, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These statements are based on management’s current expectations and Ritter Pharmaceuticals does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law.